Corcept Therapeutics Incorporated (NASDAQ: CORT) has recently submitted a New Drug Application (NDA) to the U.S. Food and ...
In conjunction with this strategic initiative, FTAI has also released its initial financial guidance for fiscal year 2025. The company expects 2025 adjusted EBITDA of approximately $1.1 to $1.15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback